This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 32.46% and 1.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.
Should You Buy Cardinal Health (CAH) Ahead of Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Nov 5 Earnings Roster: BDX, ABC & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Cardinal (CAH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q3.
The Zacks Analyst Blog Highlights: Newmont, Pool, Cardinal Health and American Water Works
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Newmont, Pool, Cardinal Health and American Water Works
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from gradual recovery in Clear Aligner shipment volumes in Q3.
4 Dividend Hikers to Bet On Amid Prolonged Uncertainty
by Shuvra Shankar Dey
Although it is rare to see firms raising dividends this year, Newmont Corporation (NEM), Pool Corporation (POOL), Cardinal Health (CAH) and American Water Works (AWK) have come up as exceptions.
Top Ranked Income Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 16th.